Studying C-reactive protein and D-dimer levels in blood may prevent severe complications: A study in Bangladeshi COVID-19 patients

Abstract

The ongoing COVID-19 pandemic has been a scientific, medical and social challenge. Since clinical course of this disease is largely unpredictable and can develop rapidly causing severe complications, it is important to identify laboratory biomarkers, which may help to classify patient’s severity during initial stage. Previous studies have suggested C—reactive protein (inflammatory) and D-dimer (biochemical) as an effective biomarker. The differential severity in patients across the world and our limited understanding in the progression of the disease calls for a multi-country analysis for biomarkers. Therefore, we have analyzed these biomarkers among 228 Bangladeshi COVID-19 patients. We observed significant association of COVID-19 severity with these two biomarkers. Thus, we suggest to use these biomarkers for Bangladeshi COVID-19 patients for better disease monitoring. Such validated preventive measures may decrease the case fatality ratio substantially.

Mechanisms of COVID-19 Associated Pulmonary Thrombosis: A Narrative Review

“…Inflammatory-mediated thrombosis is also supported by the similarity in terms of comorbidities and other classical risk factors for venous thromboembolic disease in patients with and without COVID-19-associated pulmonary thrombosis [ 31 , 32 ]. Elevated serum levels of CRP are associated with thrombotic disease and mortality in COVID-19 patients [ 35 , 36 , 37 , 38 ]. Moreover, CRP is an important link between inflammation and thrombosis, as it can activate the complement cascade, induce platelet adhesion to ECs, stimulate tissue factor (TF) expression by blood monocytes, and alter the fibrinolytic balance of ECs [ 39 ].…”

Analysis of prognostic factors in critically ill patients with COVID-19

“…Other factors like comorbidities, including diabetes, hypertension, and cardiovascular diseases, have also been shown to increase the risk of mortality [ 7 ]. Some studies have additionally focused on biomarkers, such as elevated D-dimer levels, C-reactive protein, and decreased lymphocyte counts as potential indicators of severe outcomes [ 8 – 10 ]. However, much of this research is generalized and does not specifically delve into predictors of mortality in critically ill patients, a gap this study aims to fill.…”